STOCK TITAN

Enanta Pharmaceuticals Inc - ENTA STOCK NEWS

Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.

Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.

Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.

Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) announced the selection of EDP-305 1.0 mg as the optimal dose after an interim analysis of the ARGON-2 Phase 2b study. The company will discontinue this trial evaluating EDP-305 as a monotherapy in favor of pursuing combination therapies for non-alcoholic steatohepatitis (NASH) through an out-licensing strategy. Data from EDP-297 indicated it is not substantially differentiated from EDP-305. Enanta aims to redirect resources toward developing treatments for hepatitis B and respiratory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) announced two poster presentations for its novel pangenotypic hepatitis B virus (HBV) core inhibitor EDP-514 at The Liver Meeting® 2021 from November 12-15, 2021. The data highlight preliminary results from a 28-day Phase 1b study in patients with chronic HBV. The presentations focus on EDP-514's ability to significantly reduce HBV DNA and RNA in viremic patients. These findings could advance Enanta's efforts in developing effective treatments for chronic HBV infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
none
-
Rhea-AI Summary

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announces that Jay R. Luly, Ph.D., President and CEO, will participate in two virtual investor conferences in September 2021. These include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Baird 2021 Virtual Global Healthcare Conference on September 14 at 12:15 p.m. ET. Webcasts will be available on Enanta's website. The company focuses on discovering small molecule drugs for viral infections and liver diseases, leveraging royalties from hepatitis C products developed with AbbVie.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) has elected Yujiro S. Hata to its Board of Directors. Hata brings over 20 years of experience in developing innovative therapies and has held key positions in several biotechnology companies. His expertise is expected to enhance Enanta's strategic direction, particularly in advancing combination therapies for viral infections and liver diseases. Hata is currently the Founder and CEO of IDEAYA Biosciences, with a track record of successful partnerships and acquisitions in the biotechnology sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
management
-
Rhea-AI Summary

Enanta Pharmaceuticals has initiated its Phase 1 clinical trial for EDP-721, an innovative oral hepatitis B virus (HBV) RNA destabilizer. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in healthy volunteers followed by chronic HBV patients. The company envisions that EDP-721, when combined with existing treatments, could lead to an all-oral regimen for achieving functional cures for HBV. Preliminary data from the first part of the study is expected in early 2022, highlighting Enanta's ongoing commitment to developing groundbreaking treatments for viral infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) reported strong fiscal third-quarter results for the period ending June 30, 2021, with total revenues of $21.6 million, up from $18.7 million in 2020. The increase is attributed to royalty revenue from AbbVie's HCV regimen, MAVYRET. The company faced a net loss of $24.0 million compared to $14.3 million the previous year, largely due to increased research and development costs. Enanta is advancing its pipeline, preparing for Phase 1 studies of EDP-235 and EDP-721, amidst a strong cash position of $372.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced the nomination of EDP-235, an oral protease inhibitor aimed at treating COVID-19. Set to advance into clinical trials early next year, EDP-235 targets conserved regions in the virus's active site, making it resistant to mutations affecting the spike protein. Promising preclinical data show EDP-235 effectively inhibits SARS-CoV-2 replication with an EC90 of 33nM and exhibits a favorable safety profile. The company plans to apply for Fast Track designation and initiate a Phase 1 study involving about 75 healthy volunteers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.87%
Tags
covid-19
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) will release its fiscal Q3 2021 financial results on August 5, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the financial results and updates on the company's R&D pipeline, which includes candidates for RSV, HBV, and NASH. Their funding comes from royalties associated with hepatitis C treatments developed in collaboration with AbbVie.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences earnings
-
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced the retirement of Nathalie Adda, M.D., Senior Vice President and Chief Medical Officer, effective February 2022, after which she will remain a consultant. Dr. Adda has been instrumental in overseeing Enanta's Clinical and Regulatory Department, contributing to the development of a pipeline of four clinical candidates targeting respiratory syncytial virus, hepatitis B virus, and non-alcoholic steatohepatitis. Enanta is now searching for her successor as it continues to advance its clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data for EDP-721, a novel oral therapy targeting hepatitis B virus (HBV). This data shows a significant reduction in HBV surface antigen levels by up to 3 logs in AAV-HBV mouse models. The research highlights EDP-721's potential as part of an all-oral regimen for HBV treatment and exhibits synergistic effects with other antiviral therapies. Phase 1 trials are expected to begin in mid-2021, with EDP-721 aimed at overcoming the limitations of existing HBV therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
Enanta Pharmaceuticals Inc

Nasdaq:ENTA

ENTA Rankings

ENTA Stock Data

108.80M
19.90M
6.58%
96.11%
12.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
WATERTOWN